NetworkNewsBreaks Archive - Page 248 of 1736

MondayJan 23, 2023 2:37 pm

NetworkNewsBreaks – Finovate VP Featured in Recent Episode of The Bell2Bell Podcast Event

Finovate host and vice president of strategy Greg Palmer is spotlighted in the latest release from the Bell2Bell Podcast. The announcement comes from IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. During the interview, Palmer and IBN host Jonathan Keim talked about the impact of the pandemic on the fintech space and how the pandemic continues to drive innovation. Calling the pandemic a “reset point,” Palmer noted that the space is seeing more early-stage companies and an increase desire by venture capitalists to engage with those early-stage companies. He observed that during the next…

MondayJan 23, 2023 1:27 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pharmaceutical Expert as New Strategic Advisor

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has a new strategic advisor. The company announced that Julian Gangolli, the former president of GW Pharmaceuticals USA, has joined Lexaria as a strategic advisor. During his time at GW Pharmaceuticals, Gangolli managed US Food and Drug Administration approval of Epidiolex(R), the only pure cannabidiol (“CBD”) drug ever approved by the agency; he also oversaw the commercialization of the drug in the United States, which ultimately led to Jazz Pharmaceuticals acquiring GW Pharmaceuticals in a $7.2 billion transaction. In addition to his work at GW Pharmaceuticals, Gangolli served as North…

MondayJan 23, 2023 1:09 pm

NetworkNewsBreaks – Jupiter Wellness Inc.’s (NASDAQ: JUPW) Redeemable Digital Coupons Now Available for Shareholders of Record

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced availability of its redeemable digital coupons for shareholders of record to claim on Upstream’s trading app. Upon successful claim, shareholders may redeem the digital coupon for a gift package of company products valued at over $179 or trade with others globally on Upstream to bring new potential customers into the community. The announcement reads, “By incorporating Upstream’s Web3 digital coupons into our strategy, we aim to provide our shareholders with first-hand experience of our products and bring new potential customers into our community to drive…

MondayJan 23, 2023 1:01 pm

NetworkNewsBreaks – QSAM Biosciences Inc. (QSAM) to Present at Emerging Growth Conference

QSAM Biosciences (OTCQB: QSAM) is developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions. The company today announced that it has been invited to present at the Emerging Growth Conference at 10:15 a.m. ET on Wednesday, Jan. 25, 2023. Leading QSAM’s presentation will be the company’s CEO Douglas Baum and other executive officers, who may subsequently open the floor for questions. Interested parties should visit https://nnw.fm/okDrp to register to attend the conference and receive any updates. An archived webcast will be made available on EmergingGrowth.com and on the Emerging Growth YouTube…

MondayJan 23, 2023 12:31 pm

NetworkNewsBreaks – Calix Inc. (NYSE: CALX) Featured in Roth Equity Research Report

Calix (NYSE: CALX) was featured in a recent equity research report published by Roth Capital Partners LLC. An excerpt of the report reads, “We expect Calix to report meet or beat 4Q22 results (1/26 BMO) driven by continued strong demand of the ongoing broadband ‘super cycle’ (unmet demand, increasing broadband requirements and a favorable regulatory environment). Misconstrued comments around macro supply chain issues have driven the stock down 18% since Jan 10th. Demand and supply are not the constraints, but rather skilled labor for deployments (this is nothing new). We would use the weakness as an entry point into the…

MondayJan 23, 2023 11:06 am

NetworkNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Unveils Streamlined, Automated Carrier Onboarding Process

Freight Technologies (NASDAQ: FRGT), a technology company whose custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine-learning, offers a real-time portal for B2B cross-border shipping and domestic shipping within the USMCA region, has announced a new, automated and effortless carrier onboarding process. The new process, states the company, makes it even easier qualified carriers to sign up and move loads with Fr8App. The announcement noted that qualified carriers who sign up on the Fr8App platform, can approved and unlock all the platform options in only minutes; users simply follow step-by-step instructions that are provided. The new streamlined process…

MondayJan 23, 2023 10:59 am

NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. According to the update, the study used an industry-standard animal model to compare weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours prior to infection experienced no significant weight loss over the six-day trial, whereas the untreated control group’s weight declined 12% on average, a highly statistically significant difference (p<0.0005). “We…

FridayJan 20, 2023 3:40 pm

NetworkNewsBreaks – Upstream’s Stance to ‘Optimize Compliance, Not Replace It’ Featured in New Article

In a new article, Upstream shines the spotlight on Genesis and Gemini’s SEC charges and the risks of unregulated securities. “Last week, it was reported that through their cryptocurrency loan program, Gemini Earn, Genesis Global Capital LLC, and Gemini Trust Company LLC were charged by the Securities and Exchange Commission ‘SEC’ for soliciting and selling unregistered securities to 340,000 retail investors… It will be eye-opening to see how the two firms and the crypto market as a whole respond to these crackdowns. Much of the industry is still operating in a legal gray area. This news and the overall state…

FridayJan 20, 2023 12:27 pm

NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology

Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic technology drug candidate, toward clinical trials… Short for Apoptotic DNA Immunotherapy(TM), ADI(TM) is a nucleic acid-based technology platform that utilizes a novel antigen-specific approach to induce immune tolerance by mimicking the way the body naturally induces tolerance to its own tissues. The technology, the company…

FridayJan 20, 2023 12:12 pm

NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Eying Broad Market Opportunities for Its Liposomal Joint Homing Peptide

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently revealed positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. “Silo Pharma provided an update on the ongoing study as of Dec. 30, 2022. During the study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis drug versus the drug alone. The drug used in the study was dexamethasone (“DEX”), a corticosteroid used for its anti-inflammatory and immunosuppressant effects. Earlier results of the same study successfully demonstrated that the…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

NetworkNewsBreaks